Private, focused on the development of IV Citrulline for rare pediatric diseases. First indication, the prevention of significant sequelae of pediatric acute cardiopulmonary bypass-induced lung injury, Ph 3 trial is ongoing. After receiving FDA and EMA registration, the company sold Cholbam, for bile acid synthesis defects and peroxisomal disorders, to Retrophin (RTRX) in 2015, providing an ongoing, quarterly revenue stream.
Autoimmune, Metabolic Disorders, Rare Disease
729 E. Pratt St
Baltimore, MD 21202
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Upcoming Company Event Participation
Hamptons CEO Roundtable 2019
August 15, 2019